Which approach focuses on reducing harm and meeting individuals where they are in their substance use journey?

Which approach focuses on reducing harm and meeting individuals where they are in their substance use journey?

• A. Personalized Medicine With Genetics And Biomarkers
• B. Digital Health Interventions
• C. New Pharmacotherapies Targeting Craving
• D. Expanded Harm-Reduction Approaches

Answer: (D)

Harm reduction centers on reducing negative health and social consequences of substance use by meeting people where they are in their journey, prioritizing safety and autonomy over insisting on abstinence. This approach uses practical, nonjudgmental strategies like naloxone distribution, needle/syringe programs, overdose prevention, safer-use education, and broad access to healthcare and social supports, even if someone isn’t aiming to quit immediately. The emphasis is on reducing mortality and morbidity and supporting engagement with treatment when the individual is ready. Other approaches—such as tailoring treatment based on genetics and biomarkers, using digital tools to support behavior change, or developing new medications to curb craving—play important roles, but they don’t inherently center the philosophy of reducing harm by meeting people where they are. Expanded harm-reduction approaches best fit the described goal.

Harm reduction centers on reducing negative health and social consequences of substance use by meeting people where they are in their journey, prioritizing safety and autonomy over insisting on abstinence. This approach uses practical, nonjudgmental strategies like naloxone distribution, needle/syringe programs, overdose prevention, safer-use education, and broad access to healthcare and social supports, even if someone isn’t aiming to quit immediately. The emphasis is on reducing mortality and morbidity and supporting engagement with treatment when the individual is ready. Other approaches—such as tailoring treatment based on genetics and biomarkers, using digital tools to support behavior change, or developing new medications to curb craving—play important roles, but they don’t inherently center the philosophy of reducing harm by meeting people where they are. Expanded harm-reduction approaches best fit the described goal.